For elderly or comorbid patients, the high toxicity of powerful, time-limited combination therapies can outweigh their efficacy. A less harsh, continuous monotherapy is often preferable as it better preserves quality of life, even if it doesn't offer a treatment-free interval or a theoretical "100% life back."

The treatment backbone for Ph+ ALL is shifting away from intensive chemotherapy like hyper-CVAD. Chemotherapy-free regimens combining blinatumomab with a TKI (preferably ponatinib) are becoming the new standard, showing outcomes that are at least as good as, and likely better than, traditional chemotherapy.

The blinatumomab/ponatinib combination for Ph+ B-ALL achieves deep remissions, allowing nearly 80% of patients to avoid allogeneic stem cell transplants. This signals a new paradigm where avoiding the significant toxicities and quality of life impairments of transplant is a primary treatment goal, not just a secondary benefit.

Early data for BCL6 degraders in DLBCL is highly promising, representing a new class of targeted therapy. This approach, similar to degraders in breast and prostate cancer, could become a significant future treatment beyond established pathways.

The FRONT-MIND trial's positive result for Tafa-Len-R-CHOP must be contextualized. A key eligibility criterion was a diagnosis-to-treatment interval under 28 days. This selected for patients with rapidly progressing, aggressive disease, creating a higher-risk population than in other trials and likely explaining the R-CHOP arm's weaker performance.

A 15-year follow-up of a SWOG clinical trial shows a significant portion of follicular lymphoma patients treated with R-CHOP remain disease-free. This challenges the long-held belief that the disease is incurable, shifting the paradigm towards a curative intent.

Due to a 20% misclassification rate with the Hans algorithm for determining cell of origin, clinicians use an IPI score of 2 or greater as the primary criterion for selecting Polatuzumab-R-CHOP. This avoids potentially giving 1 in 5 patients the wrong therapy based on an imperfect biomarker.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

An expert treating DLBCL states they no longer use bispecific antibodies as monotherapy. Combining them with partners like chemotherapy (GemOx) or ADCs (Polatuzumab) raises the complete response rate by 15-20%, offering a better chance of benefit for patients.